OBJECTIVES: Evaluation of the efficacy and safety of amlodipine in hypertensive children. STUDY DESIGN: A randomized, double blinded, placebo-controlled, parallel-group, dose-ranging study was conducted at 49 centers in North and South America. The primary end point was the effect of amlodipine on systolic blood pressure (BP); secondary end points included the effect of amlodipine on diastolic BP, the effect of amlodipine as a function of dose and body size, and evaluation of safety. RESULTS: We enrolled 268 hypertensive children (mean age, 12.1 +/- 3.3 years); 84 (31.3%) had primary hypertension, and 177 (66%) were boys. Amlodipine produced significantly greater reductions in systolic BP than placebo; these were -6.9 mm Hg for 2.5 mg daily (P=.045 vs placebo) and -8.7 mm Hg for 5 mg daily (P=.005 vs placebo). The underlying cause of hypertension had no effect on the response to amlodipine. There was a significant dose-response effect of amlodipine on both systolic and diastolic BP beginning at doses > or =0.06 mg/kg per day. Systolic BP < or =95(th) percentile was achieved in 34.6% of subjects with systolic hypertension. Amlodipine was well tolerated, with just 6 children withdrawn from treatment because of drug-related adverse events. CONCLUSIONS:Amlodipine effectively lowers systolic BP in a dose-dependent manner in hypertensive children who require drug treatment.
RCT Entities:
OBJECTIVES: Evaluation of the efficacy and safety of amlodipine in hypertensivechildren. STUDY DESIGN: A randomized, double blinded, placebo-controlled, parallel-group, dose-ranging study was conducted at 49 centers in North and South America. The primary end point was the effect of amlodipine on systolic blood pressure (BP); secondary end points included the effect of amlodipine on diastolic BP, the effect of amlodipine as a function of dose and body size, and evaluation of safety. RESULTS: We enrolled 268 hypertensivechildren (mean age, 12.1 +/- 3.3 years); 84 (31.3%) had primary hypertension, and 177 (66%) were boys. Amlodipine produced significantly greater reductions in systolic BP than placebo; these were -6.9 mm Hg for 2.5 mg daily (P=.045 vs placebo) and -8.7 mm Hg for 5 mg daily (P=.005 vs placebo). The underlying cause of hypertension had no effect on the response to amlodipine. There was a significant dose-response effect of amlodipine on both systolic and diastolic BP beginning at doses > or =0.06 mg/kg per day. Systolic BP < or =95(th) percentile was achieved in 34.6% of subjects with systolic hypertension. Amlodipine was well tolerated, with just 6 children withdrawn from treatment because of drug-related adverse events. CONCLUSIONS:Amlodipine effectively lowers systolic BP in a dose-dependent manner in hypertensivechildren who require drug treatment.
Authors: Jennifer S Li; Eric L Eisenstein; Henry G Grabowski; Elizabeth D Reid; Barry Mangum; Kevin A Schulman; John V Goldsmith; M Dianne Murphy; Robert M Califf; Daniel K Benjamin Journal: JAMA Date: 2007-02-07 Impact factor: 56.272
Authors: Perdita Taylor-Zapata; Carissa M Baker-Smith; Gilbert Burckart; Stephen R Daniels; Joseph T Flynn; George Giacoia; Dionna Green; Aaron S Kelly; Mona Khurana; Jennifer S Li; Charlotte Pratt; Elaine M Urbina; Anne Zajicek Journal: Pediatrics Date: 2019-05 Impact factor: 7.124
Authors: Felipe Fregni; Marta Imamura; Hsin Fen Chien; Henry L Lew; Paulo Boggio; Ted J Kaptchuk; Marcelo Riberto; Wu Tu Hsing; Linamara Rizzo Battistella; Andrea Furlan Journal: Am J Phys Med Rehabil Date: 2010-02 Impact factor: 2.159
Authors: Daniel K Benjamin; P Brian Smith; Pravin Jadhav; Jogarao V Gobburu; M Dianne Murphy; Vic Hasselblad; Carissa Baker-Smith; Robert M Califf; Jennifer S Li Journal: Hypertension Date: 2008-03-10 Impact factor: 10.190